`
`Paper No. ____
`Date filed: February 20, 2018
`
`
`
`
`
`
`Filed On Behalf Of:
`
`Novartis Pharmaceuticals Corporation
`
`By:
`
`Nicholas N. Kallas
`NKallas@fchs.com
`ZortressAfinitorIPR@fchs.com
`(212) 218-2100
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITED,
`Petitioner,
`
`v.
`
`NOVARTIS PHARMACEUTICALS CORPORATION,
`Patent Owner.
`
`
`
`Case IPR2018-00507
`Patent 8,410,131
`
`
`
`
`PATENT OWNER NOVARTIS’S RESPONSE TO
`PETITIONER WEST-WARD’S MOTION FOR JOINDER
`
`
`
`
`
`
`
`
`
`Patent Owner Novartis Pharmaceuticals Corporation (“Novartis”) does not
`
`oppose the January 17, 2018 joinder motion of West-Ward Pharmaceuticals
`
`International Limited (“West Ward”) on the conditions regarding the conduct of
`
`the joint proceeding set forth in West-Ward’s joinder motion: (i) Ward-Ward will
`
`act as a silent understudy in the joint proceeding for so long as the Petitioner
`
`Breckenridge Pharmaceutical, Inc. (“Breckenridge”) in Breckenridge
`
`Pharmaceutical, Inc. v. Novartis Pharmaceuticals Corporation, IPR2017-01592
`
`(the “Breckenridge IPR”) is in the joint proceeding; (ii) West-Ward consents to
`
`consolidated filings for all substantive papers, not exceeding the normal word
`
`count or page limits for a single party as set forth in the rules, and agrees that
`
`West-Ward will not file, or request to file, any separate briefs beyond the
`
`consolidated filings in the joint proceeding; (iii) West-Ward consents to
`
`consolidated discovery in the joint proceeding and agrees that West-Ward will not
`
`request additional cross-examination or redirect time; and (iv) unless the
`
`Breckenridge IPR has been terminated with respect to Breckenridge, West-Ward
`
`agrees that Breckenridge will be responsible for the oral argument presentation
`
`before the Board and West-Ward will not request any additional time to
`
`independently argue before the Board or attempt to submit its own demonstratives.
`
`(Paper 3 at 7-10.)
`
`
`
`1
`
`
`
`Novartis respectfully requests that the Board order West-Ward to comply
`
`with the aforementioned conditions in the joint proceeding. Precedent exists for
`
`those limitations. See, e.g., Bungie, Inc. v. Acceleration Bay, LLC, IPR2016-00934,
`
`Paper 11 (July 8, 2016) at 13-14 (granting Bungie’s motion for joinder, ordering
`
`that petitioners consolidate all briefing under the page limits of 37 C.F.R. § 42.24,
`
`and ordering that Bungie not file any additional pages to address points of
`
`disagreement with the Activision petitioners without first moving for and obtaining
`
`the Board’s permission); ZTE USA, Inc. v. Evolved Wireless LLC, IPR2016-01280,
`
`Paper 8 (Dec. 21, 2016) at 4 (consolidating identical IPR petitions sua sponte, and
`
`ordering that petitioners “will share all time permitted for depositions and will file
`
`all papers, except for papers that do not involve the other petitioner, as a
`
`consolidated paper, and that consolidated papers will not be given additional pages
`
`or words unless otherwise authorized by the Board.”). Cf. Teva Pharms. USA, Inc.
`
`v. Viiv Healthcare Co., IPR2015-00550, Paper 11 (June 25, 2015) at 6 (denying
`
`joinder where joinder raised the prospect that the parties and the Board would have
`
`to manage burdensome additional pages of briefing); Famy Care Ltd v. Allergan,
`
`Inc., IPR2017-00566, Paper 12 (July 12, 2017) at 9-10 (denying joinder where
`
`petitioner did not concede to taking a “silent understudy” role).
`
`
`
`
`
`
`
`2
`
`
`
`Respectfully submitted,
`
`
`Dated: February 20, 2018
`
`/ Nicholas N. Kallas /
`Nicholas N. Kallas
`Registration No. 31,530
`Lead Counsel for Patent Owner
`FITZPATRICK, CELLA, HARPER
`& SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`
`
`
`
`
`3
`
`
`
`CERTIFICATE OF SERVICE
`
`
`
`I certify that a copy of Patent Owner Novartis’s Response To Petitioner
`
`West-Ward’s Motion For Joinder was served on February 20, 2018 by causing it to
`
`be sent by email to counsel for Petitioner at the following email addresses:
`
`Keith A. Zullow (kzullow@goodwinprocter.com)
`
`Marta E. Delsignore (mdelsignore@goodwinprocter.com)
`
`
`
`
`
`
`
`Dated: February 20, 2018
`
`
`
`/ Nicholas N. Kallas /
`Nicholas N. Kallas
`Registration No. 31,530
`FITZPATRICK, CELLA,
`HARPER & SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`
`
`
`
`
`
`
`
`
`4
`
`